Cas:116496-16-3 2-methyl-4-propan-2-ylbenzenesulfonic acid manufacturer & supplier

We serve Chemical Name:2-methyl-4-propan-2-ylbenzenesulfonic acid CAS:116496-16-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-methyl-4-propan-2-ylbenzenesulfonic acid

Chemical Name:2-methyl-4-propan-2-ylbenzenesulfonic acid
CAS.NO:116496-16-3
Synonyms:4-isopropyl-2-methyl-benzenesulfonic acid;4-Isopropyl-2-methyl-benzolsulfonsaeure;4-ISOPROPYL-2-METHYLBENZENE-1-SULFONIC ACID
Molecular Formula:C10H14O3S
Molecular Weight:214.28100
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:1.2g/cm3
Index of Refraction:1.534
PSA:62.75000
Exact Mass:214.06600
LogP:3.44590

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 4-isopropyl-2-methyl-benzenesulfonic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-ISOPROPYL-2-METHYLBENZENE-1-SULFONIC ACID physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-ISOPROPYL-2-METHYLBENZENE-1-SULFONIC ACID Use and application,4-ISOPROPYL-2-METHYLBENZENE-1-SULFONIC ACID technical grade,usp/ep/jp grade.


Related News: Zhejiang Huahai Pharmaceutical: It is a leading company in domestic APIs, especially in the field of cardiovascular drugs. 2-methyl-4-propan-2-ylbenzenesulfonic acid manufacturer In recent years, China’s bulk drug companies have gradually completed the upgrade of the product structure of bulk raw materials to specialty raw materials and intermediates. The industry’s leading companies have further developed the research and development layout of high-barrier generic pharmaceutical raw materials with multiple patents that have not yet expired. 2-methyl-4-propan-2-ylbenzenesulfonic acid supplier GlaxoSmithKline (GSK) is at the bottom of the top 20 list with the lowest percentage R&D spend/annual revenue at 12%.�� 2-methyl-4-propan-2-ylbenzenesulfonic acid vendor From the three-month point onward, 84.5% of uMRD patients maintained that deep remission in the blood to the 12-month assessment. These data show the new combo can deliver “very durable remissions” for the vast majority of patients, Tendler said. 2-methyl-4-propan-2-ylbenzenesulfonic acid factory More than 2,000 new cases were also recorded in the country in the past 24 hours, raising the worldwide total to nearly 14,380, according to Chinese and World Health Organization data. The vast majority of the cases are inside China; about 100 cases have been confirmed in at least 23 other countries.